Accelerate time to clinic

A process and analytics AAV platform approach

What is a “platform” at OXB?

- A standardized, end-to-end process
- Seamless integration of proprietary technologies and processes that drive performance
- Built for consistency, speed, scalability, and regulatory confidence

The inAAVate™ platform technologies



1. **Dual plasmid and pHelper**: Improved productivity and packaging efficiency
2. **Vector production and Lysis**: Optimized and scalable process for improved productivity and packaging
3. **Purification**: Robust and scalable AF and AEX process for high% full capsid and control of PTMs for improved potency
4. **Formulation**: Broad applicability to multiple serotypes. Demonstrated stability for 18 months at 2 – 8°C

How the inAAVate™ platform streamlines your path to clinic



How do we achieve these timelines?

- Key innovations throughout the upstream and downstream process leading to higher titers and consistent performance at any scale
- Expertise for accelerated analytical development and qualification

Partner with OXB for your gene therapy

Faster to clinic, without compromise

- 7–9-months timeline from project start to GMP release
- Proven fast-track pathways with built-in scalability

Proven platform, streamlined process

- InAAVate™ platform is optimized for speed, quality, and flexibility
- Pre-qualified assays reduce method development time by months

Decisions backed by data, delivered sooner

- Rapid feasibility screening and at-risk GLP tox material generation
- Early readouts on potency, deamidation, and vector quality

Results that advance your program

- Delivered >90% full capsid AAV in 6 weeks for studies
- Functional assay development & qualification in 6 months

Let’s deliver life-changing therapies together

To discuss your project, please contact our team at **partnering@oxb.com**

OXB | June 2025